TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20664284
Drug: Telmisartan-based therapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan-based therapy
Study: 20664284
Drug: CCB-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB-based therapy
Study: 15180174
Drug: Sigmasporin Microoral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sigmasporin Microoral 100 mg
Study: 15180174
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral 100 mg
Study: 11475748
Drug: Oxymatrine 600
Normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine 600 mg per day intramuscularly
Study: 11475748
Drug: General liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: General liver protective agents (vitamins)
Study: 28093896
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) and topical administration of tranexamic acid (TXA) (15 mg/kg i.v. and 1.0 g topically)
Study: 24635496
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (400 μg) 4 hourly
Study: 24635496
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of intracervical Foley catheter and intravaginal misoprostol (400 μg) 4 hourly
Study: 19486375
Drug: PALS after
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALS after treatment modelling intervention
Study: 8924192
Drug: Nortriptyline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline with medication clinic (no IPT)
Study: 8924192
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with medication clinic
Study: 22835900
Drug: Biocompatible PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible PD fluids (neutral-pH, low glucose degradation product 1.5% glucose solution; 1.1% amino acid solution; 7.5% icodextrin)
Study: 20644121
Drug: AIDA-2000 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AIDA-2000 treatment including anthracycline-based consolidation and all-trans retinoic acid (ATRA) for 15 days during each consolidation.
Study: 20644121
Drug: AIDA-2000 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AIDA-2000 treatment for high-risk patients including anthracycline-based consolidation and ATRA.
Study: 20644121
Drug: AIDA-0493 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AIDA-0493 treatment including cytarabine-containing regimens for high-risk patients.
Study: 20644121
Drug: AIDA-0493 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AIDA-0493 treatment including cytarabine-containing regimens for low/intermediate-risk patients.
Study: 9607056
Drug: Five-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-valent pneumococcal conjugate vaccine (PCV); three doses separated by two months; types 6B, 14, 18C, 19F, and 23F
Study: 9607056
Drug: Saline placebo;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo; three doses
Study: 2096747
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose atracurium/lidocaine combination
Study: 31426362
Drug: ω3‐PUFA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω3‐PUFA alone (800 mg DHA and 225 mg EPA daily)
Study: 30246185
Drug: Fo3 (fixed-on-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fo3 (fixed-on-3) implants
Study: 30246185
Drug: Fo4 (fixed-on-4)
Normalized name: 2-Phenylbenzopyran-4-one
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fo4 (fixed-on-4) implants
Study: 23895820
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (VitD3) supplementation, 2,000 IU oral daily for 6 weeks
Study: 14684758
Drug: Asian ginseng
Normalized name: ASIAN GINSENG
DrugBank: Panax ginseng whole (DB14284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asian ginseng (0, 1, 2, and 3 g)
Study: 10871810
Drug: Neuromotor rehabilitative
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromotor rehabilitative treatment
Study: 9180065
Drug: Flexibility exercises
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexibility exercises and relaxation therapy for 12 weeks
Study: 9180065
Drug: Graded aerobic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded aerobic exercise after crossover from flexibility treatment
Study: 9180065
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise treatment
Study: 8466022
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g/250 mL normal saline)
Study: 8466022
Drug: Saline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (250 mL normal saline)
Study: 28340145
Drug: NKTR-181 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 (100 mg, 200 mg, 400 mg)
Study: 28340145
Drug: NKTR-181 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 (400 mg)
Study: 26135957
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of SCREAM Theater intervention
Study: 26135957
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of SCREAM Theater intervention
Study: 22773673
Drug: Mini-screw implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-screw implant
Study: 16515105
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine, 1 ml (30 mg) of ketorolac and 9 ml of saline intra-articularly (Group C)
Study: 16515105
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of intra-articular saline and 10 ml of 0.25% bupivacaine (Group B)
Study: 16515105
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of intra-articular saline (Group A)
Study: 14527527
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with sertraline and cognitive-behavior therapy (CBT)
Study: 10515020
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment (n = 15)
Study: 3046626
Drug: metoprolol (M)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol (M) 200 mg SR qd
Study: 3046626
Drug: low-Na/high-K salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-Na/high-K salt (S) 2 g bid
Study: 30654882
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Study: 28882385
Drug: Vibrating mesh
Normalized name: MIcroAir Vibrating Mesh Nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating mesh (VM) with 5000 μg salbutamol
Study: 28882385
Drug: Jet nebulizers
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet nebulizers (JN) with 5000 μg salbutamol
Study: 28882385
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with AeroChamber Vent (MDI-AV) with 1600 μg salbutamol
Study: 24273930
Drug: Urtica dioica
Normalized name: Urtica Dioica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtica dioica leaf extract (500 mg capsule every 8 hours for 3 months)
Study: 20467757
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg i.v. bolus 30 min before TMZ)
Study: 12239424
Drug: Seresis (antioxidative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seresis (antioxidative combination containing carotenoids, vitamins C and E, selenium, and proanthocyanidins)
Study: 7923235
Drug: Vigabatrin (gamma-vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma-vinyl GABA) treatment, initial dose of 10 mg/kg per day progressively increased up to a maximum of 140 mg/kg per day, in addition to conventional concomitant therapy.
Study: 12410546
Drug: valepotriates (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: valepotriates (mean daily dose: 81.3 mg)
Study: 12410546
Drug: diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (mean daily dose: 6.5 mg)
Study: 25106708
Drug: PLIF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLIF with porous ceramic corundum implants
Study: 11856620
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated influenza vaccine (LIV)
Study: 11856620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LIV and IIV (LIV/IIV)
Study: 2190537
Drug: Cepharanthin (CEP)
Normalized name: Cephalanthus occidentalis bark extract
DrugBank: Cepharanthine (DB16824)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cepharanthin (CEP) 60 mg/day p.o.
Study: 2190537
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no CEP administration)
Study: 340643
Drug: Intramuscular nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nalbuphine (3 and 6 mg or 6 and 12 mg)
Study: 340643
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (4 mg and 8 mg)
Study: 340643
Drug: Intramuscular nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nalbuphine
Study: 340643
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine and nalbuphine
Study: 31163012
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy of adjuvant radiotherapy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m2 docetaxel once per week (Cohort A)
Study: 31163012
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy of adjuvant radiotherapy with a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day (Cohort B)
Study: 25757757
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy and hematoma volume
Study: 20689451
Drug: NSAIDs (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (1200 mg)
Study: 10815854
Drug: Troglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone therapy
Study: 1479419
Drug: Intramuscular recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular recombinant alpha 2b interferon (3 x 10(6)) administered every second evening for 6 months
Study: 1479419
Drug: Aspecific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspecific treatment
Study: 6335848
Drug: Conventional three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional three doses of DPT 3 months apart
Study: 6335848
Drug: Both immunized
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both immunized groups (2-dose and 3-dose)
Study: 9672328
Drug: Ketoprofen 75
Normalized name: ketoprofen 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 75 mg/day
Study: 9672328
Drug: Acetaminophen 4000
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4000 mg/day
Study: 28222674
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 130/0.4 administration
Study: 28222674
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate Ringer's solution 7.5 mL/kg
Study: 24194421
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (daily 25 mg)
Study: 23031470
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g FB/kg DM diet
Study: 23031470
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g FB/kg DM diet
Study: 23031470
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g FB/kg DM diet)
Study: 23031470
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g FB/kg DM diet
Study: 23031470
Drug: Highest level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest level of FB (150 g FB/kg DM diet)
Study: 19435954
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy using a closed-loop system (AP group)
Study: 19435954
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy using the sliding-scale method (SS group)
Study: 17302746
Drug: 1% luliconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% luliconazole cream
Study: 17302746
Drug: 0.5% luliconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% luliconazole cream
Study: 17302746
Drug: 0.1% luliconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% luliconazole cream
Study: 15366590
Drug: Shuizhitong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuizhitong capsule (SZT)
Study: 1827011
Drug: Isradipine MR
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine MR 5 mg once daily
Study: 1827011
Drug: Isradipine MR
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine MR 10 mg once daily
Study: 1827011
Drug: Isradipine given
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine given twice daily (13 +/- 2 mg total daily dose)
Study: 1827011
Drug: Modified-release isradipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release isradipine (isradipine MR) once daily
Study: 766142
Drug: Prednisolone 3
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 3 mg
Study: 30608465
Drug: EHR-generated medication
Normalized name: Ehrlichia canis
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR-generated medication lists in admission packets
Study: 21330250
Drug: Cobalt-chromium drug-eluting
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt-chromium drug-eluting stents
Study: 21330250
Drug: Stainless steel
Normalized name: stainless steel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stainless steel drug-eluting stents
Study: 19183164
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a quantified peach extract for Pru p 3, duration: 6 months
Study: 19183164
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a quantified peach extract for Pru p 3
Study: 15277165
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g/d)
Study: 11808847
Drug: Oxytocin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (16 IU) administered intranasally to 49 subjects
Study: 11808847
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of 54 subjects with no prior oxytocin treatment
Study: 9735932
Drug: Microencapsulated lambdacyhalothrin
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated lambdacyhalothrin for bednet treatment
Study: 2902642
Drug: Zuclopenthixol decanoate
Normalized name: zuclopenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuclopenthixol decanoate injection (mean dosage 123 mg/week)
Study: 30427829
Drug: rcAd26.MOS1.HIV‐Env vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rcAd26.MOS1.HIV‐Env vaccine (10^8 to 10^11 rcAd26 VP)
Study: 25374187
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (4,500 cGy of radiation at 180 cGy per day plus chemotherapy with cisplatin and 5‐fluorouracil, in the first and the end four days of radiotherapy)
Study: 17981439
Drug: Flaxseed (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40 g daily for 12 months)
Study: 15514916
Drug: Corticosteroids as
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids as part of antileukemic therapy
Study: 12351462
Drug: Repaglinide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (4 mg t.i.d.)
Study: 12351462
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 or 1,000 mg t.i.d., dose unchanged)
Study: 30126325
Drug: Lidocaine/Phenylephrine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/Phenylephrine administered with a nasal nebulizer
Study: 30126325
Drug: Lidocaine/Phenylephrine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/Phenylephrine administered with a nasal spray
Study: 24533048
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 80 ppm
Study: 23059166
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (extended-release)
Study: 23059166
Drug: Quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine IR (immediate-release)
Study: 16792320
Drug: Aprotinin in
Normalized name: aprotinin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin in the dose of 3 ppm KIU
Study: 8533869
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (NP) infusion for 60 min, decreasing mean arterial blood pressure to 50 mm Hg.
Study: 8533869
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NP infusion).
Study: 8533869
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (NP) infusion for 60 min.
Study: 31599043
Drug: 25.2 g
Normalized name: Veltassa 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25.2 g oral patiromer plus standard of care (SOC)
Study: 28188124
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioral therapy for insomnia (CCBT‐I) as an adjunctive treatment
Study: 17577465
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg BID
Study: 17577465
Drug: Dipyrone 1000
Normalized name: dipyrone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1000 mg QID
Study: 7036196
Drug: Isocarboxazid (Marplan)
Normalized name: isocarboxazid Oral Tablet [Marplan]
DrugBank: Isocarboxazid (DB01247)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isocarboxazid (Marplan) 20 mg daily, increased to achieve 90% platelet MAO inhibition
Study: 30928020
Drug: Platelet treatment
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet treatment
Study: 30928020
Drug: TGF-β type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-β type I receptor (TβR I) inhibitor A83-01
Study: 25378647
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl (low dose, 1/50th of rescue morphine dose)
Study: 25378647
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl (high dose, 1/25th of rescue morphine dose)
Study: 25378647
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (active control)
Study: 15203809
Drug: Small lapses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small lapses during treatment
Study: 15203809
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between drug treatment and lapse history
Study: 11943448
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 (IL-2) plus antiretroviral therapy
Study: 8464953
Drug: 60 lux
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 lux light therapy
Study: 8464953
Drug: 600 lux
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 lux light therapy
Study: 8464953
Drug: 3500 lux
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3500 lux light therapy
Study: 8464953
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three intensities of light therapy
Study: 3515509
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts (ORS) from effervescent tablets containing citrate
Study: 27654733
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (0.1% eye drops)
Study: 27654733
Drug: Sub-tenon triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-tenon triamcinolone injection (40mg/1ml)